CN1416824A - Medicament for preventing and treating myopia and asthenopia - Google Patents
Medicament for preventing and treating myopia and asthenopia Download PDFInfo
- Publication number
- CN1416824A CN1416824A CN02148926A CN02148926A CN1416824A CN 1416824 A CN1416824 A CN 1416824A CN 02148926 A CN02148926 A CN 02148926A CN 02148926 A CN02148926 A CN 02148926A CN 1416824 A CN1416824 A CN 1416824A
- Authority
- CN
- China
- Prior art keywords
- preparation
- borneolum syntheticum
- eye
- present
- adds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides one kind of eye medicament for preventing and treating myopia xerophthalmia and asthenopia caused by overuse of eyes, climniate reason, etc. The medicament can improve nutritious state and metabolism of eyeball, make eyeball grow healthy and serve as artificial tears to eliminate discomfort of eyes, and has pearl powder digest, borneol and trace element zinc as basic components and is compounded by adding other supplementary material.
Description
The present invention is a kind of control myopia and asthenopic ophthalmic preparation.Said preparation can prevent, treat adolescent myopia, can improve again the eye that causes because of dry or excess eye-using, lacrimal secretion are not enough dried, puckery, reach malaise symptoms such as asthenopia.
Myopia is harm humans, the especially modal oculopathy of teenager vision, and is the trend that increases year by year.Along with the quickening of social development paces, people life is more and more nervous, also more and more goes through evil with eye, worker before the especially long-term computer, the driver, air personnel etc. because job specification, be easy to take place dried, puckery, look symptom such as asthenopia.If there is one to truly have curative effect, the control myopia and the asthenopic medicine that have no side effect will produce good social benefit and vast market prospect.
The present invention is a basic ingredient with Margarita layer powder hydrolysate, Borneolum Syntheticum, trace element zinc (zinc gluconate) in addition, and in preparation, can increase the preparation viscosity materials, can overcome the above problems well.
Margarita layer powder is the nearly internal layer of the shell (being Concha Margaritifera) of Margarita.The ingredient that belongs to Concha Margaritifera.Be again more medicable part in the Concha Margaritifera, nature and flavor are salty, cold, return liver, the heart two warps, the function suppressing the hyperactive liver and subsiding YANG, and arresting convulsion makes eye bright.Modern study shows and contains protein in the Margarita layer powder, can be decomposed into polypeptide and several amino acids through hydrolysis, and it also contains trace element.Its chemical constituent is similar to Margarita.
Borneolum Syntheticum nature and flavor suffering, hardship, be slightly cold, GUIXIN, spleen, lung meridian, the function causing resuscitation with aromatic drugs, clearing away heat to alleviate pain has the removing nebula function of improving eyesight; Borneolum Syntheticum promotes the effect of other drug angle of penetration envelope barrier in addition in opthalmological.
Zinc participates in retina conduction and metabolism, in the normal structure form that keeps retinal pigment epithelium, keeps aspect such as normal vision function and plays an important role.Zinc also participates in the metabolism of retinol.
Polyvinyl alcohol can increase the viscosity of medicine, the time of prolong drug effect, can play artificial tears's effect simultaneously.
The present invention adopts the now international method of setting up form deprivation myopia animal model (FDM) through animal experiment, promptly use crescent half eyelid eyeshield (translucent), be affixed on the left eye nasal side of second day chicken of birth, make it hide palpebral fissure 1/2, be upper and lower, and the pleasing to the eye light of nasal side of partial occlusion, reduce nasal side
And the visual field, top and the bottom, be subjected to the reagent thing according to group point difference, detect following project after 5 weeks respectively: 1. with the super survey of A clavus inner structure (vitreous chamber length, anterior surface of cornea are to the ophthalmic axial length of retina front interface).2. survey clavus front and back path length (AP axle) with Abbe comparator, footpath, nose temporo side equator (NT axle) and abdomen back of the body footpath (NT footpath).3. according to photo utilize that slide gauge is measured from CC to upper and lower, nasal side, 45 °, following 45 ° of nose on the temporo side, nose, and temporo on 8 equatorial radius such as following 45 ° of 45 ° and temporo.4. utilize diopter to measure the clavus dioptric.5. measure the activity level of superoxide dismutase (SOD), nitricoxide synthase (NOS) and nitric oxide (NO) in retina-pigment epithelium-choroid homogenate, above data are carried out statistical analysis handle, observe and estimate pharmacological action of the present invention.Can draw to draw a conclusion from the result who is analyzed:
Confirm that from morphology, dioptrics, many-side such as biochemical the present invention has the expansion of the clavus of inhibition FDM schematic eye eyeball, stop schematic eye dioptric negativity to increase, activate the activity of ophthalmic superoxide dismutase (SOD), nitricoxide synthase (NOS), improve the effect of nitric oxide (NO) level.
The present invention also by to the lagophthalmos test, observes the influence of the present invention to the lagophthalmos bulbar Conjunctiva Microcirculation.
The lagophthalmos that selects anterior ocular segment not have any sign is an experimental subject, right and left eyes is experimental eye, utilization is furnished with the microcirculation instrument of bulbar Conjunctiva Microcirculation image computer analytical equipment and surveys its bulbar Conjunctiva Microcirculation state, with eye dripping 0.1ml of the present invention, behind the 10min, survey its bulbar Conjunctiva Microcirculation state again, and then with eye dripping of the present invention 10 days, survey its bulbar Conjunctiva Microcirculation state, afterwards, 10% high molecular dextran (molecular weight is 210,000) is injected in anesthesia ear vein down, behind the 40min, observe the situation that microcirculation disturbance forms, survey the situation that its microcirculation disturbance improves after putting 10min of the present invention again, and each data is carried out statistical analysis handle, observe and estimate pharmacological action of the present invention.Can draw to draw a conclusion from the result who is analyzed:
Before and after eye dripping, eye dripping after 10 days, the lagophthalmos bulbar Conjunctiva Microcirculation state analysis of reuse the present invention after 10 minutes can prove that the present invention has the lagophthalmos of improvement bulbar Conjunctiva Microcirculation state, stops the formation of its microcirculation disturbance behind the injection dextran.
Animal acute toxicity test of the present invention studies show that the present invention is safer, does not find general toxic reaction as yet and to the zest of animal conjunctiva, iris and cornea tissue.
Eye irritant test of the present invention studies show that the present invention behind eye drip repeatedly, organizes equal nonirritant to lagophthalmos.
Rat long term toxicity test of the present invention: all no abnormal when giving the rat eye drip of the present invention through routine blood test, liver, renal function, organ coefficient and main organs check pathological section when continuous 6 months, show prolonged application of the present invention, do not produce cumulative toxicity.
Through clinical observation, the present invention is 68.48% to the total effective rate of child, teenage pseudomyopia vision.All the experimenter does not find all that with slit lamp examination conjunctiva, cornea, anterior chamber, iris have other ANOMALOUS VARIATIONS, does not also find that pupil changes.All patients do not have 1 example because of untoward reaction termination test midway.
The present invention proves that to child, the clinical research in 8 weeks of teenage pseudomyopia patient medication this medical instrument has the raising vision, and eliminating vision can not be lastingly, the effect of ophthalmic bloated and headache.
The present invention is different from general cycloplegic, can not cause platycoria, and is unaffected on class to child, adolescents with learning, easily accepted application by them.According to the experimental study result, it is nutrition that the present invention can increase order, and trace element supplement can resist the prolongation of testing axis oculi, significantly improves the activity of enzyme relevant with vision in the eye, improves the eye microcirculation, improves the tired ability of its tolerance, impels its function normal again.
Following each embodiment only is used for illustrating the present invention, has no to limit the meaning of protection domain of the present invention.
Embodiment 1: eye drop
Margarita layer powder 320g
Zinc gluconate 2.3g
Borneolum Syntheticum 0.3g
Sodium chloride 7.7g
Polyoxyethylene sorbitan monoleate 1g
Ethanol 1ml
Phenoxyethanol 3ml
Polyvinyl alcohol 10g
Water for injection adds to 1000ml technology:
Get Margarita layer powder, add the injection water, stir evenly, boil, continue to stir 48 hours, filter, filtrate is concentrated in right amount, puts coldly, filters standby.Other gets an amount of water for injection, adds the polyvinyl alcohol dissolving, adds zinc gluconate, sodium chloride, Margarita layer powder extracting solution more successively, and heating is stirred and made dissolving, cooling again after the heated and boiled.Other gets Borneolum Syntheticum, adds an amount of ethanol and makes dissolving, adds polyoxyethylene sorbitan monoleate, joins then in the above-mentioned solution, stirs, and adds phenoxyethanol again, adds the injection water to ormal weight, stirs evenly, and filters promptly.
Embodiment 2: gel for eye use
Margarita layer powder 320g
Borneolum Syntheticum 0.6g
Zinc gluconate 4.6g
Sodium chloride 6.6g
Borax 3g
Polyoxyethylene sorbitan monoleate 2g
Ethanol 2ml
Phenoxyethanol 3ml
Hypromellose 15g
Water for injection adds to 1000ml
Technology:
Get Margarita layer powder, add the injection water, stir evenly, boil, continue to stir 48 hours, filter, filtrate is concentrated in right amount, puts coldly, filters standby.Other gets an amount of water for injection, adds the hypromellose dissolving, adds zinc gluconate, sodium chloride, Margarita layer powder hydrolysate more successively, and heating is stirred and made dissolving, cooling again after the heated and boiled.Other gets Borneolum Syntheticum, adds an amount of ethanol and makes dissolving, adds polyoxyethylene sorbitan monoleate, joins then in the above-mentioned solution, stirs, and adds phenoxyethanol again, adds the injection water to ormal weight, stirs evenly, and filters promptly.
Embodiment 3: gel for eye use
Margarita layer powder 320g
Borneolum Syntheticum 0.6g
Zinc gluconate 4.6g
Sodium chloride 6.6g
Borax 3g
Polyoxyethylene sorbitan monoleate 2g
Ethanol 2ml
Phenoxyethanol 3ml
Carbomer 10g
Glycerol 100ml
Water for injection adds to 1000ml
Technology:
Get Margarita layer powder, add the injection water, stir evenly, boil, continue to stir 48 hours, filter, filtrate is concentrated in right amount, puts coldly, filters standby.Other gets an amount of water for injection, adds carbomer and glycerol, stirs, and adds zinc gluconate, sodium chloride, Margarita layer powder hydrolysate more successively, and heating is stirred and made dissolving, cooling again after the heated and boiled.Other gets Borneolum Syntheticum, adds an amount of ethanol and makes dissolving, adds polyoxyethylene sorbitan monoleate, joins then in the above-mentioned solution, stirs, and adds phenoxyethanol again, adds the injection water to ormal weight, stirs evenly, and filters promptly.
Claims (8)
1, a kind of ophthalmic preparation is characterized in that: it contains Margarita layer powder hydrolysate, Borneolum Syntheticum, trace element zinc isoreactivity composition, randomly also contains conventional additives and water.This ophthalmic preparation can be an eye drop, also can be gel for eye use.
2, according to the preparation of claim 1, it is characterized in that: preparation contains the soluble in water various components of Margarita layer powder by chemical method hydrolysis gained.
3, according to the preparation of claim 1, it is characterized in that: preparation contains zinc gluconate, and its content is 0.01～100mg/ml, preferred 1～5mg/ml, more preferably from about 2.3mg/ml.
4, according to the preparation of claim 1, it is characterized in that: preparation contains Borneolum Syntheticum, and its content is 0.01～100mg/ml, preferred 0.1～0.5mg/ml, more preferably from about 3mg/ml.
5, according to the preparation of claim 1 and 4, it is characterized in that: the contained Borneolum Syntheticum of preparation can be synthetic borneol (borneolum syntheticum), also can be natural Broneolum Syntheticum.
6, according to the preparation of claim 1, it is characterized in that: preparation contains the acceptable material of at least a medicine, and its consumption is enough to regulate the viscosity of preparation; Also can contain the acceptable material of a kind of medicine, make it form gel.
7, according to the preparation of claim 1 or 6, it is characterized in that: preparation contains polyvinyl alcohol, and its content is 0.1～10% (weight), preferred 0.5～2% (weight), more preferably 1% (weight).
8, according to the preparation of claim 1, it is characterized in that: preparation can contain the conventional adjuvant that hypromellose, polyacrylic acid, carbomer (Carbopol) etc. can form gel.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN02148926A CN1416824A (en) | 2002-11-12 | 2002-11-12 | Medicament for preventing and treating myopia and asthenopia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN02148926A CN1416824A (en) | 2002-11-12 | 2002-11-12 | Medicament for preventing and treating myopia and asthenopia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1416824A true CN1416824A (en) | 2003-05-14 |
Family
ID=4751573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN02148926A Pending CN1416824A (en) | 2002-11-12 | 2002-11-12 | Medicament for preventing and treating myopia and asthenopia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1416824A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1331478C (en) * | 2004-09-28 | 2007-08-15 | 苏州工业园区天龙制药有限公司 | Pearl eye drops for improving eyesight and preparation method thereof |
| CN1799559B (en) * | 2005-01-05 | 2010-05-26 | 代龙 | Chinese medicinal gel formulation, its preparation process and quality control method |
| CN111588693A (en) * | 2020-06-18 | 2020-08-28 | 广州瑞尔医药科技有限公司 | Cromolyn sodium eye drops and preparation method thereof |
-
2002
- 2002-11-12 CN CN02148926A patent/CN1416824A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1331478C (en) * | 2004-09-28 | 2007-08-15 | 苏州工业园区天龙制药有限公司 | Pearl eye drops for improving eyesight and preparation method thereof |
| CN1799559B (en) * | 2005-01-05 | 2010-05-26 | 代龙 | Chinese medicinal gel formulation, its preparation process and quality control method |
| CN111588693A (en) * | 2020-06-18 | 2020-08-28 | 广州瑞尔医药科技有限公司 | Cromolyn sodium eye drops and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3500255B1 (en) | Ophthalmic pharmaceutical compositions and uses relating thereto | |
| US20210259961A1 (en) | Pharmaceutical composition for preventing and treating nitm and medical use thereof | |
| CN108578523A (en) | Prevent the gasification infiltration fat glasses and preparation method thereof of macular degeneration cataract myopia | |
| Nebbioso et al. | Intracameral lidocaine as supplement to classic topical anesthesia for relieving ocular pain in cataract surgery | |
| CN1416824A (en) | Medicament for preventing and treating myopia and asthenopia | |
| CN100563628C (en) | A kind of Bendalysine eye gel preparation and preparation method thereof | |
| CN206566238U (en) | A kind of Chinese medicine nano magnetite for treating cataract myopia is smoked to treat piece glasses | |
| Kondrot | Improvement in vision parameters for participants treated with alternative therapies in a 3-day program | |
| CN100577187C (en) | Chinese medicine preparation for treating eye fatigue and its preparing process | |
| CN101229365A (en) | Applications of nerve growth factor(NGF) on preparing medicine for treating pathological myopia | |
| Wilson et al. | Edema of the corneal stroma induced by cold in trigeminal neuropathy | |
| RU2460502C1 (en) | Method of treating beginning age cataract | |
| Kartasasmita et al. | The effectiveness of continuous intravitreal adrenaline as mydriatic adjuvant on pars plana vitrectomy in diabetic patient, a randomized clinical trial | |
| Sposato et al. | Axonal transport deficit in the optic nerve of rats with inherited retinitis pigmentosa and experimentally induced glaucoma | |
| Jin et al. | Efficacy and safety of intravenous injection of lidocaine in the treatment of acute primary angle-closure glaucoma: a pilot study | |
| RU2268689C9 (en) | Method for developing a depot of medicinal substances in the field of ophthalmology | |
| RU2239436C1 (en) | Agent for treatment of dry eye syndrome as complication after ophthalmic infection | |
| CN100337621C (en) | Application of aspartic acid and its salt | |
| Cramp | Reported cases of reactions and side effects of the drugs which optometrists use | |
| Kumar | ROLE OF TARPANA WITH PHALTRIKADI GHRITA IN THE MANAGEMENT OF DWITIYA PATALGATA TIMIRA WSR TO PRESBYOPIA | |
| WO2022221351A1 (en) | Treatment of neuropathic corneal pain with ngf | |
| CN116270442A (en) | Ophthalmic preparation for correcting near vision | |
| CN116869991A (en) | Application of naringenin in preparation of medicine for treating and/or preventing eye diseases | |
| CA3218870A1 (en) | Pharmaceutical composition for preventing or treating diabetic eye disease comprising sglt-2 inhibitor | |
| KR20230007245A (en) | Compositions for preventing or treating of ocular disease comprising imidazole derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |